Dimitris Kalofonos

USPTO Granted Patents = 12 (Patent Applications = 5)

CIPO Patents = 1 (Patent Applications = 1)

EPO Patents = 3 (Patent Applications = 4)

Average Co-Inventor Count = 3.6

ph-index = 5

Forward Citations = 76(Granted Patents)

Company Filing History:

Bionevia Pharmaceuticals, Inc.

Years Active: 2009-2019

Loading Chart...

12 patents (USPTO):Sort by Forward Citations

Abstract keywords

1. 10464912 - Choline cocrystal of epalrestat (2019-11-05),

2. 9611234 - Choline cocrystal of epalrestat (2017-04-04),

3. 9447056 - Solid forms of epalrestat (2016-09-20),

4. 9032215 - Management of access control in wireless networks (2015-05-12),

5. 8906948 - Choline cocrystal of epalrestat (2014-12-09),

6. 8868105 - Method and apparatus for generating location stamps (2014-10-21),

7. 8697735 - Solid forms of epalrestat (2014-04-15),

8. 8639810 - Access rights used for resource discovery in peer-to-peer networks (2014-01-28),

9. 8271649 - Access rights used for resource discovery in peer-to-peer networks (2012-09-18),

10. 8037519 - Apparatus and method for managing access to one or more network resources (2011-10-11),

11. 7764981 - System and method for managing a wireless connection to reduce power consumption of a mobile terminal (2010-07-27),

12. 7574510 - Systems, nodes, and methods for dynamic end-to-end session-enhancing services for transport-level-based connections (2009-08-11),

Certainly! Here is an article about the inventor Dimitris Kalofonos:

Title: Innovator Spotlight: Dimitris Kalofonos - Pioneering Advances in Pharmaceutical Therapies

Introduction:

Dimitris Kalofonos, a prolific inventor based in Cambridge, MA, has made significant contributions to the field of pharmaceuticals through his groundbreaking patented inventions. With a total of 12 patents to his name, Dimitris Kalofonos continues to drive innovation in the healthcare industry.

Latest Patents:

One of Dimitris Kalofonos' latest patents is the Choline cocrystal of epalrestat. This novel invention involves a choline cocrystal of 5-[(1Z.2E)-2-methyl-3-phenylpropenylidene]-4-oxo-2-thioxo-3-thiazolidineacetic acid. The patent describes the preparation, characterization, and therapeutic use of this unique cocrystal in treating diabetic complications, homocystinuria, aldose reductase inhibition, and cardioprotection in non-diabetic patients.

Career Highlights:

Dimitris Kalofonos has honed his expertise while working at renowned companies such as Nokia Corporation and Bionevia Pharmaceuticals, Inc. His experience and innovative spirit have propelled him to the forefront of pharmaceutical research and development.

Collaborations:

Throughout his career, Dimitris Kalofonos has collaborated with esteemed professionals in the field, including Isabel Kalofonos and G Patrick Stahly. These collaborations have led to the successful realization of groundbreaking inventions and their subsequent patents.

Conclusion:

In conclusion, Dimitris Kalofonos stands as a trailblazing inventor dedicated to advancing pharmaceutical therapies and improving healthcare outcomes. His commitment to innovation and collaboration underscores his significant contributions to the industry, making him a driving force in the realm of patentable inventions.

This text is generated by artificial intelligence and may not be accurate.